Ripple effects: How U.S. FDA layoffs threaten global health in low- and middle-income countries and weaken US competitiveness
As the U.S. Food and Drug Administration (FDA) faces significant staffing reductions, there could be ripple effects for US companies and leadership in the biomedical space, as well as for other countries that depend on the FDA's regulatory leadership to enable access to essential health technologies.